Iovance Biotherapeutics is trading 10.4% lower at $7.79 amid broad market and biotech-sector weakness; no new company-specific negative catalyst was identified today.
- Major U.S. indexes were lower, and XBI fell 5.19%.
- November 5 earnings showed revenue of $121.5 million, adjusted loss of $0.05 per share, and full-year revenue guidance reaffirmed at $410 million to $420 million.
- Recent lung-cancer data predates this session and does not establish a new reason for the decline.